ADPRS and cancer: However, despite a great interest in PARP1 as a target for cancer therapy and the arising therapeutic potential of PARG inhibition (Chen and Yu, 2019; Lord and Ashworth, 2017; Nagashima et al., 2020; Pillay et al., 2019; Slade, 2020), the relative contribution of ARH3 and PARG in regulating the levels of ADPr in human cells remains unclear.